They also reported high levels of POSTN could predict shorter progression-free survival following first-line chemotherapy by analysing on a set of 85 ovarian tumors as well as on an independent validation dataset containing 138 ovarian patients from the chemo-treatment arm of the ICON7 trial recurrent tumors [21]. This evidence concerns the gene POSTN and ovarian neoplasm.